New drug aims to stop transplant attack on the body
NCT ID NCT04859946
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This phase 2 trial tests whether the drug itacitinib, given with standard care, can prevent graft-versus-host disease (GVHD) in people who receive a donor stem cell transplant for blood cancers. GVHD happens when the donor cells attack the patient's body. The study includes 31 adults aged 18 to 70 who are getting a matched donor transplant. Researchers will track how many develop moderate to severe GVHD within 100 days and how long they stay free of both GVHD and cancer relapse.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Itacitinib (a drug that may calm the immune system)
- What this could lead to
- If it works, this could point toward a way to prevent graft-versus-host disease, a serious complication of donor stem cell transplants.
- What could go wrong
- This is a small, early-phase trial with only 31 participants, so results may not apply to everyone. Itacitinib may not reduce GVHD and could have side effects like infection risk.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOLOGIC AND LYMPHOCYTIC DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Blood cancer transplant study tests safer GVHD prevention
- New drug combo aims to tame deadly transplant complication
- Scientists seek immune system clues from cancer patients and healthy volunteers
- Can a psoriasis drug stop transplant rejection?
- Engineered immune cells aim to tame chronic GVHD
- Can a drug combo stop AML from coming back?